Business
Seres Therapeutics to Present at CARB-X Investor Day
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership accelerat
About this update from Seres Therapeutics, Inc.
[{"type":"image","alt":"Seres Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Seres Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":205,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AevgeV1boJs7rC.lO5CETw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE0OQ--/https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37","width":205,"height":85}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership accelerating the development of new antibacterial products to address drug-resistant bacteria. The CARB-X Investor Day brings together pharmaceutical and biotech product developers, investors, and partners working to combat antimicrobial resistance (AMR). The World Health Organization declared AMR as a top ten global public health threat, with estimates that yearly deaths may reach 10 million by 2050, putting mortality due to AMR on par with deaths due to cancer. The event will feature presentations on innovative therapeutics from recipients of CARB-X grants, providing opportunities for collaboration and funding support.","length":1119,"tagName":"p"},{"type":"text","content":"At the meeting, Elizabeth Halvorsen, Ph.D., Senior Director of Translational Biology at Seres, will provide an overview of the Company’s therapeutic platform and the productive, long-term collaboration with CARB-X. In 2025, Seres received a non-dilutive award from CARB-X for up to $3.6 million, representing the Company’s second CARB-X award, to support development of an oral liquid formulation based on SER-155 strains, now referred to as SER-428, for dosing in patients who cannot take oral capsules such as intubated patients in the medical ICU, and other medically vulnerable patients at high risk of AMR infections. Seres has a...